Protocol Title: A phase 1/2, open-label, multi-center study of ZN-c3 administered in combination with encorafenib and cetuximab in adults with metastatic colorectal cancer.

Sponsor: Pfizer

Protocol Number: Z0011001

Key Criteria

·         stage IV colorectal carcinoma
·         Documented evidence of a BRAF V600E mutation in tumor tissue or blood
·         1 measurable lesion per RECIST 1.1
·         Archival or new/fresh tissue for retrospective analysis of BRAF v600e
·         Disease progression after 1 or 2 prior regimens for metastatic disease

Talking Points

Scroll to Top